» Articles » PMID: 35076322

Computed Tomography-Guided Percutaneous Radiofrequency Ablation in Older Adults With Early-Stage Peripheral Lung Cancer: A Retrospective Cohort Study

Overview
Journal Cancer Control
Specialty Oncology
Date 2022 Jan 25
PMID 35076322
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To evaluate the feasibility, safety, and efficacy of computed tomography(CT)-guided percutaneous radiofrequency ablation (RFA) in medically inoperable older adults with clinical stage I non-small cell lung cancer (NSCLC).

Patients And Methods: We retrospectively reviewed the records of medically inoperable older adults (≥70 years) with clinical stage I NSCLC who underwent percutaneous multi-tined electrode RFA at our institution between January 2014 and December 2018. We analyzed the patients' characteristics, therapy response, survival, as well as the procedure-related complications.

Results: Eighteen patients (10 men and 8 women) with a mean age of 75.9 (71-85) years were treated in during the study period. The median tumor size was 25 mm (range, 19-43 mm); 10 and 8 cases involved stage T1 and T2a disease, respectively. The median follow-up duration was 25 (11-45) months. RFA was technically successful for all 18 lesions, with no treatment-related mortality. The disease control rate was 83.3% (15/18 lesions). There were 6 cases of pneumothorax: one symptomatic case requiring thoracic drainage, and five requiring no treatment. Minor complications, including pulmonary infection, chest pain, fever, and cough, were treated within 4 days (range, 1-4 days). The progression-free survival rates were 83.3%, 64.9%, and 51.9% 1, 2, and 3 years, respectively. The corresponding overall survival rates were 92.2%, 81.5%, and 54.3%, respectively.

Conclusions: CT-guided percutaneous RFA is safe and effective in medically inoperable patients with stage I NSCLC and could be an alternative therapeutic strategy, particularly in older adults with early-stage peripheral lung cancer.

Citing Articles

Safety and efficacy of percutaneous biopsy and microwave ablation in patients with pulmonary nodules on antithrombotic therapy: A study with rivaroxaban bridging.

Wang N, Xue T, Zheng W, Shao Z, Liu Z, Dai F Thorac Cancer. 2024; 15(28):1989-1999.

PMID: 39155057 PMC: 11444927. DOI: 10.1111/1759-7714.15425.


Enhancing precision in lung tumor ablation through innovations in CT-guided technique and angle control.

Hung W, Tsai S, Wu T, Tu H, Lin H, Su C Thorac Cancer. 2024; 15(11):867-877.

PMID: 38419563 PMC: 11016418. DOI: 10.1111/1759-7714.15255.


Radiofrequency ablation for stage <IIB non-small cell lung cancer: Opportunities, challenges, and the road ahead.

Zhao Q, Wang J, Fu Y, Hu B Thorac Cancer. 2023; 14(32):3181-3190.

PMID: 37740563 PMC: 10643797. DOI: 10.1111/1759-7714.15114.


Locoregional Thermal and Chemical Tumor Ablation: Review of Clinical Applications and Potential Opportunities for Use in Low- and Middle-Income Countries.

Quang T, Yang J, Mikhail A, Wood B, Ramanujam N, Mueller J JCO Glob Oncol. 2023; 9:e2300155.

PMID: 37625104 PMC: 10581629. DOI: 10.1200/GO.23.00155.


Case report: Radiofrequency ablation combined with biopsy for Cushing's syndrome due to ectopic ACTH lesions in the lung.

Zhang X, Meng L, Xiao Y, Chen Z Front Oncol. 2022; 12:1059308.

PMID: 36465403 PMC: 9716141. DOI: 10.3389/fonc.2022.1059308.

References
1.
Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K . Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004; 101(7):1623-31. DOI: 10.1002/cncr.20539. View

2.
Doi H, Nakamatsu K, Nishimura Y . Stereotactic body radiotherapy in patients with chronic obstructive pulmonary disease and interstitial pneumonia: a review. Int J Clin Oncol. 2019; 24(8):899-909. DOI: 10.1007/s10147-019-01432-y. View

3.
Zhu J, Yan T, Morris D . A systematic review of radiofrequency ablation for lung tumors. Ann Surg Oncol. 2008; 15(6):1765-74. DOI: 10.1245/s10434-008-9848-7. View

4.
Ambrogi M, Fanucchi O, Cioni R, Dini P, De Liperi A, Cappelli C . Long-term results of radiofrequency ablation treatment of stage I non-small cell lung cancer: a prospective intention-to-treat study. J Thorac Oncol. 2011; 6(12):2044-51. DOI: 10.1097/JTO.0b013e31822d538d. View

5.
McGhana J, Dodd 3rd G . Radiofrequency ablation of the liver: current status. AJR Am J Roentgenol. 2001; 176(1):3-16. DOI: 10.2214/ajr.176.1.1760003. View